AI-powered Pathology

Transforming Cancer Diagnosis

  • Deployed in multiple digital workflows and used by pathologists in everyday practice
  • Clinical grade accuracy
  • Improved productivity and shorter turnaround time
  • Reduced error rate and 100% quality control
  • AI-based diagnostic tools: case prioritization worklist, slide viewer, IHC preordering, cancer heatmaps, grading, measurements, non-cancer findings, AI-driven reporting

Prostate cancer is among the most common malignant diseases in men worldwide, with more than a million new cases each year. Accurate and timely diagnosis is instrumental in guiding treatment decisions and improving survival rates.

However, accurate and rapid analysis of prostate biopsies remains a challenge, as increasing case volumes are intensified by subjectivity in Gleason grading, the small size of certain tumors, the large number of tissue cores per case and multiple other reasons.

Powered by AI and serving the world’s leading physicians, health systems and diagnostic providers, Ibex’s Prostate is a clinical-grade solution that assists pathologists in improving the detection and grading of prostate cancer.

Clinically Proven Excellence

Outstanding outcomes in rigorous clinical studies at multiple institutes across the world, performed in different workflows and on various scanning systems and staining platforms1,2,3

Accuracy in Cancer Detection

– AUC 0.991
– Sensitivity 98.4%
– Specificity 97.3%

AI vs. Microscope in Primary Diagnosis

– 37% productivity gain and 27% reduction in diagnosis time
– Significantly lower rate of discrepancy with AI (4.84%) vs. microscope (7.13%)

Gleason Grading and More

Gleason 6 vs. ≥7 AUC – 0.941
Gleason 3-4 vs. ≥5 AUC – 0.971
Perineural Invasion AUC – 0.957
Read more on The Lancet

Gleason heatmap

Perineural invasion heatmap


Interview on the live deployment of Ibex AI Prostate at CorePlus in Puerto Rico


Article on the roll out of Ibex AI Prostate at the Betsi Cadwaladr University Health Board in Wales


Clinical study on using Ibex AI in primary diagnosis of prostate biopsies

Ibex’s prostate solution is CE marked (IVDD) and registered with the UK MHRA and ANVISA in Brazil. The First Read solution for prostate is also CE marked under IVDR.  Ibex Prostate is for Research Use Only (RUO) in the United States and not cleared by the FDA. Contact us for more information, including indication for use and regulatory approval in other countries.

1) Pantanowitz et al., An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study; The Lancet Digital Health, August 2020
2) Raoux et al., Novel AI-Based Solution for Supporting Primary Diagnosis of Prostate Cancer Increases the Accuracy and Efficiency of Reporting in Clinical Routine; USCAP 2021
3) Comperat et al., Clinical Level AI-Based Solution for Primary Diagnosis and Reporting of Prostate Biopsies in Routine Use: A Prospective Reader Study; The European Congress of Pathology 2021